ADMA Biologics, Inc. cash flow to debt ratio of 63.09% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

ADMA Biologics, Inc.'s free cash flow has decreased -74.73% from $110.10M last year to $27.82M, signaling decreasing performance

ADMA Biologics, Inc.'s debt to equity ratio is 0.52, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

ADMA Biologics, Inc.'s debt has increased relative to shareholder equity from 0.24 last year to 0.52 today, signaling weakened financials

ADMA Biologics, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

ADMA Biologics, Inc.'s interest coverage ratio of 28.59 indicates that earnings with good margin can cover interest payments on company debt

ADMA Biologics, Inc.'s profit margin has decreased (-30.03%) in the last year from 46.35% to 32.43%, signaling decreasing performance

ADMA Biologics, Inc.'s short-term assets of $466.51M exceed its short-term liabilities of $69.54M

ADMA Biologics, Inc.'s return on assets of 24.86% is higher than the 5.00% threshold, indicating efficient asset utilization

ADMA Biologics, Inc.'s return on equity of 38.97%, is higher than 15.00%, indicating good performance

ADMA Biologics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ADMA Biologics, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

ADMA Biologics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

ADMA Biologics, Inc. has a free cash flow yield of 1.35%, which is below the 2.00% threshold, indicating limited cash return relative to market value

ADMA Biologics, Inc.'s yearly earnings has decreased -25.67% since last year from $197.67M to $146.93M, signaling decreasing performance

ADMA Biologics, Inc.'s yearly revenue has increased 19.63% since last year from $426.45M to $510.17M, signaling increasing performance

ROIC 27.81% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

ADMA Biologics, Inc.'s 3-year revenue CAGR of 49.05% is positive, indicating growing revenue over the past 3 years

ADMA Biologics, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

ADMA Biologics, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

ADMA Biologics, Inc. has insufficient data to evaluate this check.

ADMA Biologics, Inc. has an earnings yield of 7.90%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

ADMA Biologics, Inc. is overvalued relative to its fair value price of 5.85 based on EBITDA multiple model

ADMA Biologics, Inc. has an EV/EBITDA ratio of 10.35x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

ADMA Biologics, Inc. is overvalued relative to its fair value price of 4.28 based on Earnings Fair Value model

ADMA Biologics, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.

ADMA Biologics, Inc. has a price-to-book ratio of 5.36x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

ADMA Biologics, Inc. has a price-to-sales ratio of 4.11x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue